Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Age De-Escalation/Dose Escalation Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in an African Population of Adults and Children in a Setting of Perennial Malaria Transmission

NCT06408857 is registered in ClinicalTrials.gov with Gates Medical Research Institute as lead sponsor.

NCT NCT06408857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06408857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Age De-Escalation/Dose Escalation Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in an African Population of Adults and Children in a Setting of Perennial Malaria Transmission
Lead sponsor
Gates Medical Research Institute
Phase
Phase 1
Overall status
Completed
Start date
March 28, 2025
Completion date
May 28, 2026
Enrollment
125 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers